The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effects of immediate elevation of inflammatory cytokines after platinum, pemetrexed, and pembrolizumab on antitumor efficacy in advanced non-squamous, non-small cell lung cancer.
 
Yuichi Ozawa
Honoraria - AstraZeneca Japan; Chugai Pharma; Daiichi Sankyo; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Speakers' Bureau - AstraZeneca Japan; Chugai Pharma; Daiichi Sankyo; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Yasuhiro Koh
Honoraria - Amgen; Chugai Pharma; Cytogen; Guardant Health; Novartis; Tosoh Corporation
Consulting or Advisory Role - Tosoh Corporation
Research Funding - Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Takeda (Inst); Zeon Corporation
 
Hiroaki Akamatsu
Honoraria - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; Janssen; Kyowa Kirin International; Lilly; MSD; Nippon Kayaku; Novartis; Novocure; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; GlaxoSmithKline; Janssen; Sandoz
Research Funding - Amgen (Inst); Chugai Pharma (Inst); Novartis (Inst)
 
Ryota Shibaki
No Relationships to Disclose
 
Mitsuo Osuga
No Relationships to Disclose
 
Masanori Nakanishi
No Relationships to Disclose
 
Nobuyuki Yamamoto
Honoraria - Abbvie; Acuuray; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Guardant Health; Janssen; Kyorin; Kyowa Kirin International; Lilly Japan; Merck; Miyarisan pharmaceutical; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda; TERUMO; Tsumura & Co.
Consulting or Advisory Role - Amgen; AstraZeneca; Chugai Pharma; MSD; Novartis; Ono Pharmaceutical
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); EPS Corporation (Inst); IQvia (Inst); Janssen (Inst); Lilly Japan (Inst); Mebix (Inst); Medpace (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst); Prime-R (Inst); Syneos Health (Inst)